Cover Image

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2014. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Pharmaceuticals & Healthcare, Global, Deal Summary

  • 2.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2014
  • 2.2. Pharmaceuticals & Healthcare, Global, Major Deals, February 2014
    • 2.2.1. Actavis to Acquire Forest Labs for US$25 Billion
    • 2.2.2. Merck Enters into Licensing Agreement with Ablynx for Cancer Immunotherapy
    • 2.2.3. Medtronic Completes Public Offering of Notes for US$2 Billion
    • 2.2.4. Smith & Nephew Receives Regulatory Approval to Acquire ArthroCare for US$1.7 Billion
    • 2.2.5. Mallinckrodt Completes Acquisition of Cadence Pharma for US$1.4 Billion in Tender Offer
  • 2.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2014
  • 2.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2014

3. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type

  • 3.1. Pharmaceuticals & Healthcare, Global, M&A, February 2014
    • 3.1.1. Top M&A Deals in February 2014
    • 3.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2013 - February 2014
  • 3.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2014
    • 3.2.1. Top Equity Offering Deals in February 2014
    • 3.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2013 - February 2014
  • 3.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2014
    • 3.3.1. Top PE/VC Deals in February 2014
    • 3.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2014
    • 3.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2014
    • 3.3.4. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, September 2013-February 2014
    • 3.3.5. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2013-February 2014

4. Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2014

  • 4.1. Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2014
  • 4.2. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2013 - February 2014
  • 4.3. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2014
    • 4.3.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2014
  • 4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • 4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2013 - February 2014
  • 4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2013 - February 2014
  • 4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2013 - February 2014

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2014

  • 5.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2014
  • 5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2014
    • 5.2.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2014
    • 5.2.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2014
    • 5.2.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2014
  • 5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2013 - February 2014
  • 5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2013 - February 2014
  • 5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2013 - February 2014
  • 5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2013 - February 2014

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

  • 6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2014
    • 6.1.1. Oncology - Deals of the Month
  • 6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2014
    • 6.2.1. Central Nervous System - Deals of the Month
  • 6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2014
    • 6.3.1. Infectious Diseases - Deals of the Month
  • 6.4. Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, February 2014
    • 6.4.1. Metabolic Disorders - Deal of the Month
  • 6.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2014
    • 6.5.1. Immunology - Deal of the Month
  • 6.6. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2014
    • 6.6.1. Cardiovascular - Deal of the Month
  • 6.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, February 2014
    • 6.7.1. Gastrointestinal - Deals of the Month

7. Deal Summary by Geography

  • 7.1. Pharmaceuticals & Healthcare, North America Deals, February 2014
    • 7.1.1. North America - Deals of the Month
  • 7.2. Pharmaceuticals & Healthcare, Europe, Deals, February 2014
    • 7.2.1. Europe - Deals of the Month
  • 7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2014
    • 7.3.1. Asia-Pacific - Deals of the Month
  • 7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2014
    • 7.4.1. Rest of the World - Deals of the Month

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors

  • 8.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2013 - February 2014
  • 8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2013 - February 2014

9. Further Information

  • 9.1. Methodology
  • 9.2. About GlobalData
  • 9.3. Disclosure information
  • 9.4. Disclaimer

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, February 2014
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2014
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2014
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2013 - February 2014
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2014
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2014
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2013 - February 2014
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 2014
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2013 - February 2014
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2014
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2013 - February 2014
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2013 - February 2014
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 2014
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2014
  • Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2014
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2014
  • Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2013 - February 2014
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2014
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 35: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2013 - February 2014

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), February 2014
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 2014
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2013 - February 2014
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2013 - February 2014
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 2014
  • Figure 11:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), February 2014
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • Figure 16:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2013 - February 2014
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2013 - February 2014
  • Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 21:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, September 2013 - February 2014
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), September 2013 - February 2014
  • Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2014
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 30: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2013 - February 2014
Show More
Pricing